Table 2.
Characteristics of the NSCLC patients grouped by NLR and PLR values
| NLR | PLR | ||||||
|---|---|---|---|---|---|---|---|
| Characteristic | Cases (n, %) | Low | High | P | Low | High | P |
| Gender | 0.001 * | 0.001 * | |||||
| Male | 425 (74.7) | 121 | 304 | 122 | 303 | ||
| Female | 144 (25.3) | 79 | 65 | 22 | 122 | ||
| Age (years) | 0.380 | 0.773 | |||||
| ≤ 60 | 286 (50.3) | 106 | 180 | 74 | 212 | ||
| > 60 | 283 (49.7) | 94 | 189 | 70 | 213 | ||
| Smoking | 0.007 * | 0.001 * | |||||
| Ever | 372 (46.0) | 116 | 256 | 111 | 261 | ||
| Never | 197 (54.0) | 84 | 133 | 33 | 164 | ||
| Histological type | 0.009 * | 0.642 | |||||
| LUAD | 295 (51.8) | 121 | 174 | 70 | 225 | ||
| LUSC | 225 (39.5) | 64 | 161 | 60 | 165 | ||
| Others | 49 (8.6) | 15 | 34 | 14 | 35 | ||
| Tumor length | 0.001 * | 0.001 * | |||||
| ≤ 4 | 277 (48.7) | 124 | 153 | 89 | 188 | ||
| > 4 | 292 (51.3) | 76 | 216 | 55 | 237 | ||
| Differentiation | 0.342 | 0.913 | |||||
| Well | 182 (32.0) | 57 | 125 | 48 | 134 | ||
| Moderately | 195 (34.3) | 69 | 126 | 49 | 146 | ||
| Poorly | 192 (33.7) | 74 | 118 | 47 | 145 | ||
| T stage | 0.001 * | 0.072 | |||||
| T1 | 144 (25.3) | 70 | 74 | 46 | 98 | ||
| T2 | 284 (49.9) | 97 | 187 | 68 | 216 | ||
| T3 | 107 (18.8) | 27 | 80 | 26 | 81 | ||
| T4 | 34 (6.0) | 6 | 34 | 4 | 30 | ||
| N stage | 0.235 | 0.249 | |||||
| N0 | 223 (39.2) | 82 | 141 | 61 | 162 | ||
| N1 | 142 (25.0) | 52 | 90 | 41 | 101 | ||
| N2 | 201 (35.3) | 65 | 136 | 41 | 160 | ||
| N3 | 3 (0.5) | 1 | 2 | 1 | 2 | ||
| Lymph node metastasis | 0.530 | 0.376 | |||||
| Negative | 223 (39.2) | 36 | 38 | 61 | 162 | ||
| Positive | 346 (60.8) | 54 | 72 | 83 | 263 | ||
| TNM stage | 0.107 | 0.099 | |||||
| I | 147 (25.8) | 60 | 87 | 43 | 104 | ||
| II | 177 (31.1) | 65 | 112 | 50 | 127 | ||
| III | 245 (43.1) | 75 | 170 | 51 | 194 | ||
| Operation duration (minutes) | 0.187 | 0.334 | |||||
| < 150 | 302(53.1) | 114 | 118 | 71 | 231 | ||
| ≥ 150 | 267 (46.9) | 86 | 181 | 72 | 194 | ||
| Intraoperative blood loss (mL) | 0.848 | 0.036 * | |||||
| < 150 | 170 (29.9) | 61 | 109 | 33 | 137 | ||
| ≥ 150 | 399 (70.1) | 139 | 260 | 111 | 288 | ||
*
P < 0.05 is considered significant. LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; NLR, neutrophil‐lymphocyte ratio; NSCLC, non‐small cell lung cancer; PLR, platelet‐lymphocyte ratio; TNM, tumor node metastasis.